Free Trial

Ligand Pharmaceuticals (LGND) Earnings Date, Estimates & Call Transcripts

Ligand Pharmaceuticals logo
$114.64 +0.70 (+0.61%)
(As of 12/20/2024 05:16 PM ET)
Get Ligand Pharmaceuticals Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ligand Pharmaceuticals and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

LGND Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

LGND Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Ligand Pharmaceuticals Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany Guidance
Q1 20241$0.75$0.75$0.75 
Q2 20241$0.67$0.67$0.67 
Q3 20241$0.80$0.80$0.80 
Q4 20241$0.75$0.75$0.75 
FY 20244$2.97$2.97$2.97 
Q1 20251$0.98$0.98$0.98 
Q2 20251$1.01$1.01$1.01 
Q3 20251$1.00$1.00$1.00 
20253$2.99$2.99$2.99 
Q1 20261$1.19$1.19$1.19 

Ligand Pharmaceuticals Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
8/6/2024Q2 2024$1.06$1.40+$0.34$4.72$33.04M$41.50M
5/7/2024Q1 2024$0.83$3.84+$3.01-$3.15$27.92M$30.90M
2/27/2024Q4 2023$0.24$0.79+$0.55$0.55$24.54M$28.10M
11/8/2023Q3 2023$0.68$1.02+$0.34$2.16$27.22M$32.87M
8/8/2023Q2 2023$0.76$1.42+$0.66$2.07$24.74M$26.37M
5/4/2023Q1 2023$0.89$2.28+$1.39$1.59$33.55M$43.98M
⭕ [URGENT] Buy Alert just triggered (Ad)

My absolute favorite stock just hit a critical "buy now" trigger price.

2/22/2023Q4 2022$1.23$1.36+$0.13$0.52$39.63M$50.40M

Ligand Pharmaceuticals Earnings - Frequently Asked Questions

Ligand Pharmaceuticals issued an update on its FY 2025 earnings guidance on Wednesday, December, 11th. The company provided earnings per share guidance of 6.000-6.250 for the period, compared to the consensus estimate of 6.030. The company issued revenue guidance of $180.0 million-$200.0 million, compared to the consensus revenue estimate of $183.1 million.

Ligand Pharmaceuticals (NASDAQ:LGND) has a recorded annual revenue of $152.42 million.

Ligand Pharmaceuticals (NASDAQ:LGND) has a recorded net income of $52.15 million. LGND has generated $2.51 earnings per share over the last four quarters.

Ligand Pharmaceuticals (NASDAQ:LGND) has a trailing price-to-earnings ratio of 45.67 and a forward price-to-earnings ratio of 66.27.

Ligand Pharmaceuticals's earnings are expected to grow from $1.73 per share to $3.95 per share in the next year, which is a 128.32% increase.

More Earnings Resources from MarketBeat



This page (NASDAQ:LGND) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners